# Natural Killer Cell (CYNK-001) Infusions in Adults with AML

> **NCT04310592** · PHASE1 · TERMINATED · sponsor: **Celularity Incorporated** · enrollment: 27 (actual)

## Conditions studied

- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Neoplasms by Histologic Type
- Neoplasms
- Immunosuppressive Agents
- Immunologic Factors
- Physiological Effects of Drugs
- Alkylating Agents
- Antimetabolites, Antineoplastic
- Antiviral Agents
- Analgesics, Non-narcotic
- Anti-infective Agents
- Analgesics
- Peripheral Nervous System Agents
- Hematologic Diseases
- Hematologic Neoplasms
- Leukemia in Remission
- Relapsed Adult AML
- Refractory AML

## Interventions

- **BIOLOGICAL:** CYNK-001

## Key facts

- **NCT ID:** NCT04310592
- **Lead sponsor:** Celularity Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-12
- **Primary completion:** 2023-01-20
- **Final completion:** 2023-04-28
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04310592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04310592, "Natural Killer Cell (CYNK-001) Infusions in Adults with AML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04310592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*